In the SENSCIS-ON trial, two-thirds of patients with systemic sclerosis-associated interstitial lung disease who continued nintedanib after completion of the SENSCIS trial maintained stable lung function or had improvement in lung function.“The SENSCIS-ON trial provides important new evidence about the longer-term use of nintedanib in people living with systemic sclerosis-associated ILD,
The American Society of Nephrology has called on Congress to increase funding for the U.S. transplant system by $8 million in fiscal year 2025, according…
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV…
BOSTON — More than 40% of patients with difficult-to-treat pathogens were prescribed older, generic agents despite the FDA approval of several new gram-negative antibiotics, findings…
BOSTON — “We should be embracing [AI] and trying to make this a priority to get this right, because I don’t know any alternative to…
Sublingual immunotherapy tablets improved quality of life for patients with allergic rhinitis with and without conjunctivitis, according to a review published in The Journal of…
BOSTON — Time-restricted eating did not result in more weight loss vs. a usual eating pattern, suggesting that overall caloric intake may have a larger…
BOSTON — The ACP has been designated as a GRADE Center based on its developmental processes for guidelines, becoming the first organization in the U.S…
DENVER — While rare and associated with a limited differential diagnosis, abrupt-onset dementia may be treatable with prompt recognition and early intervention, according to a…
The latest news from the ACP Internal Medicine Meeting along with researcher interviews and clinician insight.
ATLANTA — Pregnant women with fewer economic resources may still be at elevated risk for CVD despite a low score on a CVD risk calculator,…
